MPT Q1 net income $0.05 diluted vs $1.05 YoY, NFFO $0.37; cuts 2023 guidance, declares $0.29 dividend

MEDICAL PROPERTIES TRUST INC

2023-Q1 EPS reported $0.05 revenue$350,211,000

Net income $33M ($0.05/diluted) vs $632M ($1.05) in Q1 2022; includes $90M impairment for hospital sales.
Normalized FFO $222M ($0.37/diluted) vs $282M ($0.47) YoY, driven by no Prospect revenue and asset sales.
Agreed to sell Healthscope portfolio for AUD$1.2B; Prime to repurchase three hospitals for ~$100M in Q3.
2023 guidance revised: net income $0.06-$0.17 per share, NFFO $1.50-$1.61; debt reduction expected ~$1.4B.
Sued Viceroy Research for defamation; regular Q2 dividend of $0.29 per share declared.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MEDICAL PROPERTIES TRUST INC reported the first quarter ended March 31, 2023 results: revenue approximately $19.7 billion, net income $33 million ($0.05 per diluted share), EPS $0.05. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: approximately $19.7 billion
Net income: $33 million ($0.05 per diluted share)
EPS: $0.05
Guidance: reaffirmed
Result: reported results

Exact text from the filing

facilitate MPT’s conversion of certain existing and future real estate obligations of Prospect into additional managed care equity. The Company has total assets of approximately $19.7 billion, including $13.7 billion of general acute care hospitals, $2.5 billion of behavioral health facilities and $1.7 billion of post-acute facilities. MPT’s portfolio includes 444

View on SEC.gov

Browse all earnings releases →

MEDICAL PROPERTIES TRUST INC filing history →

Source: SEC EDGAR

accession 0001193125-23-120216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.